Chemoresistance remains the greatest challenge in improving survival of lung cancer patients. Lung cancer cells have greater expression than normal cells of proteins involved in detoxification of electrophiles and drugs detoxification and efflux pumps [Glutathione and Thioredoxin system and Multidrug resistance proteins] that provides intrinsic resistance against chemotherapy. Studies in project 3 have established that activation of the redox-sensitive transcription factor, Nuclear factor erythroid-2 related factor 2 (NRF2), in response to xenobiotic stress, positively regulates the expression of electrophile, xenobiotic detoxification enzymes and efflux pumps which confer cytoprotection against oxidative stress and apoptosis in normal cells. Kelch-like ECH-associated protein (KEAP1) negatively regulates NRF2 activity by targeting it for proteasomal degradation. Increasing NRF2 activity by small molecule activators might protect the lung epithelium of high risk subjects from oncogenic damage due to carcinogens. However, a surprising finding has emerged in the project that provoked re-thinking about the NRF2 pathway in terms of lung and other cancers. We have recently discovered that dysfunctional KEAP1 activity is a frequent alteration in lung adenocarcinomas which results in greater nuclear accumulation of NRF2 and enhances the transcriptional induction of electrophile, drug detoxification, and efflux proteins. Thus, unlike normal cells, lung cancer cells have unrestrained high NRF2 activity leading to therapeutic resistance. KEAP1 in the adenocarcinomas has deletions, insertions, and missense mutations in functionally important domains of the protein, and a very high percentage of loss of heterozygosity at 19p13.2, suggesting that biallelic inactivation of KEAP1 in these cancers is a common event. Mutations were detected in all stages of adenocarcinomas (including stage IA). Decreased KEAP1 activity, in-vitro, causes radio- and Chemoresistance. We have also identified mutations in KEAP1 in prostate tumors and recently similar mutations were reported in breast tumors.The new aims of this proposal are:
Specific Aim 1 : To determine the association between high NRF2 activity and Chemoresistance in non-squamous non-small cell lung cancer (NSCLC);
Specific Aim 2 : To determine whether targeted NRF2 inhibition can diminish Chemoresistancein preclinical models;
and Specific Aim 3 : To determine whether pharmacologically decreasing NRF2 activity in lung cancer can reverse Chemoresistance. Relevance to Public Health: The studies in this project have potential for both identifying biomarkers to predict drug sensitivity in patients with lung adenocarcinomas and to devise new means to reverse Chemoresistance in patients with drug-resistant tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058184-18
Application #
8403065
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-11-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
18
Fiscal Year
2013
Total Cost
$267,162
Indirect Cost
$88,268
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Hulbert, Alicia; Jusue-Torres, Ignacio; Stark, Alejandro et al. (2017) Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum. Clin Cancer Res 23:1998-2005
Zhong, Yi; Macgregor-Das, Anne; Saunders, Tyler et al. (2017) Mutant p53 Together with TGF? Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res 23:1607-1620
Chiappinelli, Katherine B; Zahnow, Cynthia A; Ahuja, Nita et al. (2016) Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res 76:1683-9
Singh, Anju; Venkannagari, Sreedhar; Oh, Kyu H et al. (2016) Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol 11:3214-3225
Chiappinelli, Katherine B; Strissel, Pamela L; Desrichard, Alexis et al. (2015) Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 162:974-86
Vendetti, Frank P; Topper, Michael; Huang, Peng et al. (2015) Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget 6:56-70
Belinsky, Steven A (2015) Unmasking the lung cancer epigenome. Annu Rev Physiol 77:453-74
Sussan, Thomas E; Gajghate, Sachin; Thimmulappa, Rajesh K et al. (2015) Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. PLoS One 10:e0116861
Kim, Jung-Hyun; Thimmulappa, Rajesh K; Kumar, Vineet et al. (2014) NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest 124:730-41
Izumchenko, Evgeny; Chang, Xiaofei; Michailidi, Christina et al. (2014) The TGF?-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74:3995-4005

Showing the most recent 10 out of 256 publications